AGMB.O (AGMB.O) News
Follow AGMB.O (AGMB.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
BRIEF — Agomab Announces First Patient Dosed In Global Nov — Era Phase 2B Study Of Ontunisertib In Fibrostenosing Crohn's Disease
Agomab Therapeutics NV: Agomab Announces First Patient Dosed In Global Nov-era Phase 2b Study Of Ontunisertib In Fibrostenosing Crohn's Disease Agomab Therapeutics Nv - Nov-era Phase 2b Study Expected To Enroll About 320
NEWS | Oct 13, 2026, 08:16 PM UTC
L
Agomab doses first patient in NOV — ERA Phase 2b trial of ontunisertib in fibrostenosing Crohn’s disease
Agomab began dosing in NOV-ERA, a global Phase 2b trial of ontunisertib for symptomatic fibrostenosing Crohn’s disease. Earlier Phase 2a STENOVA results were already presented, supporting continued late-stage development
MNA | Oct 13, 2026, 08:09 PM UTC